In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biofrontera AG

www.biofrontera.com

Latest From Biofrontera AG

Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results

Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.

Clinical Trials Dermatology

Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.

Financing Business Strategies

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Top-Line Data For Reslizumab, Erenumab And Biosimilar Rituximab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Inflammation
  • Alias(es)
  • Biofrontera Pharmaceuticals Holding AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Biofrontera AG
  • Senior Management
  • Hermann Lubbert, PhD, CEO
    Thomas Schaffer, CFO
    Christoph Dunwald, Chief Commercial Officer
  • Contact Info
  • Biofrontera AG
    Phone: (49) 214 876 00
    Hemmelrather Weg 201
    Leverkusen, 51377
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register